Exicure, Inc. - XCUR STOCK NEWS

Exicure, a leader in gene regulatory therapeutics, has announced that CEO David Giljohann will present at the BTIG Virtual Biotechnology Conference on August 9, 2021, at 2:30 PM ET. During the event, Exicure will also host one-on-one investor meetings. The company is known for its Spherical Nucleic Acid technology and is developing treatments for various diseases, including neurology and immuno-oncology. Notably, Exicure is working on XCUR-FXN for Friedreich’s ataxia and cavrotolimod (AST-008) for advanced solid tumors.

Ipsen and Exicure Inc. have entered a collaboration to develop novel Spherical Nucleic Acids (SNAs) targeting Huntington’s disease and Angelman syndrome. Ipsen will pay Exicure $20 million upfront, with potential for up to $1 billion in milestone payments and royalties. SNAs are expected to enhance drug delivery to hard-to-reach areas like the brain. Both diseases currently lack approved disease-modifying therapies, presenting a significant market opportunity. The partnership aims to leverage Ipsen's expertise in neuroscience and Exicure's innovative delivery technology to address these unmet medical needs.

Exicure, Inc. (NASDAQ: XCUR) will host a virtual R&D Day on July 15, 2021, highlighting its neuroscience pipeline, particularly XCUR-FXN for Friedreich's Ataxia (FA). This program targets the disease's molecular cause and is on track for IND filing in late Q4 2021. The event will also cover advancements in therapies for SCN9A-related neuropathic pain and CLN3 Batten Disease. CEO Dr. David Giljohann emphasizes the potential of their SNA platform to address neurological disorders with promising data that may benefit patients.

Exicure, Inc. (NASDAQ: XCUR) announced that CEO David Giljohann will present at the Ladenburg Thalmann 2021 Healthcare Conference on July 13, 2021, from 1:00-1:25 PM in Track One. The panel discussion will be webcast, with replays available for 30 days on Exicure's website. The company focuses on gene regulatory and immunotherapeutic drugs utilizing its proprietary Spherical Nucleic Acid (SNA™) technology, aimed at treating neurological, immuno-oncologic, and inflammatory diseases. Exicure is developing XCUR-FXN for Friedreich’s ataxia and cavrotolimod for advanced solid tumors.

Exicure, Inc. (NASDAQ: XCUR) has announced CEO David Giljohann's participation in two upcoming conferences. The BIO Digital 2021 conference will feature a corporate update presentation on June 10, 2021, available for on-demand viewing. The BMO Biopharma Day will include a rare disease panel on June 22, 2021, streamed live at 10:30 AM ET. Exicure focuses on developing innovative therapeutics leveraging its Spherical Nucleic Acid technology, targeting conditions such as Friedreich’s ataxia and advanced solid tumors.

Exicure, Inc. (NASDAQ: XCUR) has appointed Brian C. Bock as its new Chief Financial Officer, effective immediately. Bock brings over 20 years of experience in life science investment banking and healthcare strategy, previously serving as Managing Director at Lincoln International. His expertise is expected to enhance Exicure’s business strategy and valuation. The company granted Bock an inducement stock option for 600,000 shares at an exercise price of $1.54, vesting over four years. Exicure focuses on developing therapies using its proprietary Spherical Nucleic Acid technology for various diseases.

Exicure, Inc. (NASDAQ: XCUR) reported Q1 2021 results, highlighting significant advancements in clinical programs and board expansion. The FDA granted Fast Track and Orphan Drug designations for cavrotolimod (AST-008) aimed at treating advanced Merkel cell carcinoma and squamous cell carcinoma. The company is on track to submit an IND for XCUR-FXN for Friedreich's Ataxia by year-end 2021. Financially, the company reported a net loss of $12.5 million, up from a $1.2 million net income year-over-year, while cash reserves decreased to $67.4 million.

Exicure, Inc. (NASDAQ: XCUR) reported that Northwestern University researchers successfully utilized its gold-nanoparticle SNA technology in a first-in-human trial targeting glioblastoma (GBM). The phase 0 trial showed that intravenously administered siRNA-based SNAs can safely cross the blood-brain barrier and target the oncogene Bcl2L12. These findings, published in Science Translational Medicine, mark a significant milestone for Exicure’s technology in treating GBM. The company also plans to file an IND for Friedreich's ataxia by the end of 2021.

Exicure, Inc. (NASDAQ:XCUR) reported impressive financial results for 2020, achieving $16.6 million in revenue, up from $1.3 million in 2019, primarily due to a collaboration with AbbVie. The net loss reduced to $24.7 million from $26.3 million year-over-year. Key advancements included the initiation of IND-enabling studies for XCUR-FXN targeting Friedreich’s ataxia and multiple FDA designations for cavrotolimod (AST-008), enhancing its oncology pipeline. Despite COVID-19 related delays, Exicure expects sufficient cash runway for the next 12 months to support ongoing trials.